

Upshot Of ‘Skinny Label’ Case May Go Beyond Pharma

In a recently published Law360 article, Banner Witcoff’s Jason Shull discusses the U.S. Supreme Court agreeing to review *Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc.*, a case that sits at the intersection of patent law, U.S. Food and Drug Administration regulation, and generic drug competition.

The article explains *Hikma v. Amarin* matters now, how it fits within existing inducement doctrine and what practitioners should be thinking about as the case proceeds.

The full article can be found by [clicking here](#).

Posted: February 4, 2026